News

Quidel has reported total revenue of $56.2m, an increase of 76% from $31.9m, for third quarter of fiscal year ended September 30, 2009. During the quarter the company

Highlights: Earnings per diluted share in the third quarter of 2009 increased to $0.50 from $0.15 per diluted share in the same period of the prior year, an

GlaxoSmithKline (GSK) has received approval for Cervarix in Japan, which becomes the first cervical cancer vaccine to be approved by the Japanese Ministry of Health, Labour and Welfare

Teva Pharmaceutical Industries (Teva) has commented on the abbreviated new drug application (ANDA) containing a Paragraph IV certification for Copaxone (glatiramer acetate injection), filed by Mylan Pharmaceuticals. Teva

Cancer Therapeutics has signed a letter of intent to acquire another 26% interest in NanoTherapies, bringing the former’s stake to 51% and giving it a controlling interest of

Targacept has presented data from its recently completed phase 2b clinical trial of TC-5214 as an augmentation (add-on) treatment in subjects with major depressive disorder, or MDD. Reportedly,

GlaxoSmithKline (GSK) has reported results from a second clinical trial of its pandemic (H1N1) adjuvanted vaccine, which demonstrated that one dose of the vaccine can provide a strong

As part of an investigator-initiated five patient pilot study in Japan, Cytori was informed that stem and regenerative cells from a patient’s own fat tissue were used to

Alios BioPharma has bagged US Patent No. 7,597,884 from US Patent and Trademark Office (USPTO). The company has claimed that numerous compounds from its glycoengineering program including its